SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cleveland Biolabs Inc. Receives FDA Agreement on Pivotal Animal Efficacy Studies for Development of CBLB502 (Entolimod™) as Radiation Countermeasure